Vanda Pharmaceuticals (NASDAQ:VNDA) Director Purchases 3,447 Shares of Stock

Key Points

• Director Charles Cliff Duncan bought shares on November 3–5, investing about $38,000 and increasing his ownership stake.
• Vanda shares fell 7.5% to $3.59, near their 12-month low, despite quarterly results beating analyst estimates for both earnings per share and revenue.
• Analyst views are mixed: the consensus rating is “Hold,” with a $13.50 price target, while six analysts rate the stock Buy and two rate it Sell.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) Director Charles Cliff Duncan bought 3,447 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Wednesday, November 4th. The stock was bought at an average price of $3.82 per share, for a total transaction of $13,167.54. Following the completion of the acquisition, the director directly owned 102,898 shares of the company's stock, valued at $393,070.36. The trade was a 3.47% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

Charles Cliff Duncan also recently made the following trade(s):

• On Thursday, November 5th, Charles Cliff Duncan acquired 5,803 shares of Vanda Pharmaceuticals stock. The stock was acquired at an average cost of $3.80 per share, with a total value of $22,051.40.
• On Tuesday, November 3rd, Charles Cliff Duncan purchased 750 shares of Vanda Pharmaceuticals stock. The shares were acquired at an average price of $3.80 per share, for a total transaction of $2,850.00.

Vanda Pharmaceuticals Stock Down 7.5%

NASDAQ:VNDA traded down $0.29 during trading hours on Thursday, reaching $3.59. The company had a trading volume of 1,239,112 shares, compared to its average volume of 1,499,630. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 0.01. The firm has a market cap of $217.09 million, a price-to-earnings ratio of -0.78 and a beta of 0.74. The business's 50-day simple moving average is $4.70 and its two-hundred day simple moving average is $6.16. Vanda Pharmaceuticals Inc. has a twelve month low of $3.57 and a twelve month high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its earnings results on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.31. Vanda Pharmaceuticals had a negative return on equity of 62.70% and a negative net margin of 119.87%. The company had revenue of $69.81 million for the quarter, compared to analyst estimates of $69.20 million. On average, equities analysts expect that Vanda Pharmaceuticals Inc. will post -2.53 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. B. Riley Financial reissued a "buy" rating and issued a $12.00 price objective (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. Weiss Ratings reissued a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a report on Thursday, October 15th. Wall Street Zen upgraded Vanda Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, October 31st. HC Wainwright restated a "buy" rating on shares of Vanda Pharmaceuticals in a report on Monday. Finally, Zacks Research cut Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Tuesday, October 6th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Vanda Pharmaceuticals currently has an average rating of "Hold" and a consensus price target of $13.50.

Trending Headlines about Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Director Charles Cliff Duncan bought shares on November 3, 4 and 5, investing about $38,000 in total and increasing his stake. The purchases may signal confidence in Vanda’s prospects. SEC filing
• Neutral Sentiment: HC Wainwright maintained its “Buy” rating and raised its FY2026 loss estimate to $2.45 per share from $3.03, while improving its Q4 2026 estimate. That outlook is partly offset by a wider projected FY2027 loss of $1.02 per share, versus $0.94 previously.
• Negative Sentiment: HC Wainwright lowered its loss-per-share forecasts for Q2, Q3 and Q4 2027, suggesting weaker earnings expectations for much of that year. VNDA is also trading near its 12-month low and below its 50- and 200-day moving averages, reflecting continued share-price weakness.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of hedge funds have recently modified their holdings of VNDA. BlackRock Inc. purchased a new stake in shares of Vanda Pharmaceuticals during the second quarter worth about $46,841,000. Monaco Asset Management SAM purchased a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at $1,354,000. State Street Corp lifted its stake in Vanda Pharmaceuticals by 16.6% in the second quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company's stock worth $21,520,000 after purchasing an additional 500,843 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter worth approximately $1,317,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at $1,668,000. 88.14% of the stock is currently owned by institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda's marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.